Glenmark’s Anti-Diarrhea Drug Developed in Partnership With Salix Gets FDA Nod

by Kathy Jones on  January 3, 2013 at 7:43 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Glenmark Pharmaceuticals revealed that its anti-diarrhea drug manufactured in partnership with Salix Pharmaceuticals has been approved by the US Food and Drug Administration.
 Glenmark’s Anti-Diarrhea Drug Developed in Partnership With Salix Gets FDA Nod
Glenmark’s Anti-Diarrhea Drug Developed in Partnership With Salix Gets FDA Nod

The company said that the drug, Crofelemer 125 mg, has been approved for treating diarrhea in HIV/AIDS patients and those on anti-retroviral therapy.

Crofelemer has been developed by Glenmark who acquired the license to manufacture it from Napo Pharmaceuticals who had initially discovered the major compound used in the drug.

"This is a significant approval milestone and will enable the first NCE launch by Glenmark across emerging markets. Most importantly, this is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on anti-retovirals who experience non-infectious diarrhea, which often can lead to reduced treatment compliance. This will also help us accelerate filing across countries and also propel our development in additional diarrhea indications including the acute indications", Genlmark's chairman, Glenn Saldanha said.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive